• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

COVID-19 合并症网络在韩国住院患者中的解剖学研究。

The anatomy of COVID-19 comorbidity networks among hospitalized Korean patients.

机构信息

Department of Sociology, Korea University, Seoul, Korea.

Department of Preventive Medicine, University of Tennessee Health Science Center, Memphis, TN, USA.

出版信息

Epidemiol Health. 2021;43:e2021035. doi: 10.4178/epih.e2021035. Epub 2021 May 7.

DOI:10.4178/epih.e2021035
PMID:33971700
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8289479/
Abstract

OBJECTIVES

We aimed to examine how comorbidities were associated with outcomes (illness severity or death) among hospitalized patients with coronavirus disease 2019 (COVID-19).

METHODS

Data were provided by the National Medical Center of the Korea Disease Control and Prevention Agency. These data included the clinical and epidemiological information of all patients hospitalized with COVID-19 who were discharged on or before April 30, 2020 in Korea. We conducted comorbidity network and multinomial logistic regression analyses to identify risk factors associated with COVID-19 disease severity and mortality. The outcome variable was the clinical severity score (CSS), categorized as mild (oxygen treatment not needed), severe (oxygen treatment needed), or death.

RESULTS

In total, 5,771 patients were included. In the fully adjusted model, chronic kidney disease (CKD) (odds ratio [OR], 2.58; 95% confidence interval [CI], 1.19 to 5.61) and chronic obstructive pulmonary disease (COPD) (OR, 3.19; 95% CI, 1.35 to 7.52) were significantly associated with disease severity. CKD (OR, 5.35; 95% CI, 2.00 to 14.31), heart failure (HF) (OR, 3.15; 95% CI, 1.22 to 8.15), malignancy (OR, 3.38; 95% CI, 1.59 to 7.17), dementia (OR, 2.62; 95% CI, 1.45 to 4.72), and diabetes mellitus (OR, 2.26; 95% CI, 1.46 to 3.49) were associated with an increased risk of death. Asthma and hypertension showed statistically insignificant associations with an increased risk of death.

CONCLUSIONS

Underlying diseases contribute differently to the severity of COVID-19. To efficiently allocate limited medical resources, underlying comorbidities should be closely monitored, particularly CKD, COPD, and HF.

摘要

目的

我们旨在研究合并症如何与 2019 年冠状病毒病(COVID-19)住院患者的结局(疾病严重程度或死亡)相关。

方法

数据由韩国疾病控制与预防局国家医疗中心提供。这些数据包括 2020 年 4 月 30 日或之前在韩国出院的所有 COVID-19 住院患者的临床和流行病学信息。我们进行了合并症网络和多项逻辑回归分析,以确定与 COVID-19 疾病严重程度和死亡率相关的危险因素。结局变量是临床严重程度评分(CSS),分为轻度(不需要吸氧治疗)、重度(需要吸氧治疗)或死亡。

结果

共纳入 5771 例患者。在完全调整模型中,慢性肾脏病(CKD)(比值比[OR],2.58;95%置信区间[CI],1.19 至 5.61)和慢性阻塞性肺疾病(COPD)(OR,3.19;95%CI,1.35 至 7.52)与疾病严重程度显著相关。CKD(OR,5.35;95%CI,2.00 至 14.31)、心力衰竭(HF)(OR,3.15;95%CI,1.22 至 8.15)、恶性肿瘤(OR,3.38;95%CI,1.59 至 7.17)、痴呆(OR,2.62;95%CI,1.45 至 4.72)和糖尿病(OR,2.26;95%CI,1.46 至 3.49)与死亡风险增加相关。哮喘和高血压与死亡风险增加无统计学关联。

结论

基础疾病对 COVID-19 的严重程度有不同的影响。为了有效地分配有限的医疗资源,应密切监测基础合并症,特别是 CKD、COPD 和 HF。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/131b/8289479/aacc4f34b6dd/epih-43-e2021035f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/131b/8289479/6b7fe2d3bff3/epih-43-e2021035f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/131b/8289479/aacc4f34b6dd/epih-43-e2021035f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/131b/8289479/6b7fe2d3bff3/epih-43-e2021035f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/131b/8289479/aacc4f34b6dd/epih-43-e2021035f2.jpg

相似文献

1
The anatomy of COVID-19 comorbidity networks among hospitalized Korean patients.COVID-19 合并症网络在韩国住院患者中的解剖学研究。
Epidemiol Health. 2021;43:e2021035. doi: 10.4178/epih.e2021035. Epub 2021 May 7.
2
Eosinophilia in Asthma Patients Is Protective Against Severe COVID-19 Illness.哮喘患者的嗜酸性粒细胞增多对严重的COVID-19疾病具有保护作用。
J Allergy Clin Immunol Pract. 2021 Mar;9(3):1152-1162.e3. doi: 10.1016/j.jaip.2020.12.045. Epub 2021 Jan 23.
3
Association of pre-existing comorbidities with mortality and disease severity among 167,500 individuals with COVID-19 in Canada: A population-based cohort study.在加拿大,167500 例 COVID-19 患者中,先前存在的合并症与死亡率和疾病严重程度的关系:一项基于人群的队列研究。
PLoS One. 2021 Oct 5;16(10):e0258154. doi: 10.1371/journal.pone.0258154. eCollection 2021.
4
Prevalence of comorbidity in Chinese patients with COVID-19: systematic review and meta-analysis of risk factors.中国 COVID-19 患者合并症的患病率:危险因素的系统评价和荟萃分析。
BMC Infect Dis. 2021 Feb 22;21(1):200. doi: 10.1186/s12879-021-05915-0.
5
Prevalence and predictors of death and severe disease in patients hospitalized due to COVID-19: A comprehensive systematic review and meta-analysis of 77 studies and 38,000 patients.因 COVID-19 住院患者的死亡和重症预测因素:77 项研究和 38000 例患者的综合系统评价和荟萃分析。
PLoS One. 2020 Dec 7;15(12):e0243191. doi: 10.1371/journal.pone.0243191. eCollection 2020.
6
Prevalence of comorbidities among individuals with COVID-19: A rapid review of current literature.COVID-19 患者合并症的患病率:当前文献快速综述。
Am J Infect Control. 2021 Feb;49(2):238-246. doi: 10.1016/j.ajic.2020.06.213. Epub 2020 Jul 10.
7
Clinical determinants of the severity of COVID-19: A systematic review and meta-analysis.临床因素对 COVID-19 严重程度的影响:系统评价和荟萃分析。
PLoS One. 2021 May 3;16(5):e0250602. doi: 10.1371/journal.pone.0250602. eCollection 2021.
8
Factors affecting mortality in geriatric patients hospitalized with COVID-19.影响 COVID-19 老年住院患者死亡率的因素。
Turk J Med Sci. 2021 Apr 30;51(2):454-463. doi: 10.3906/sag-2008-91.
9
Chronic comorbidities and clinical outcomes in patients with and without COVID-19: a large population-based study using national administrative healthcare open data of Mexico.患有和未患有 COVID-19 的患者的慢性合并症和临床结局:利用墨西哥国家行政医疗保健公开数据进行的一项大型基于人群的研究。
Intern Emerg Med. 2021 Sep;16(6):1507-1517. doi: 10.1007/s11739-020-02597-5. Epub 2021 Jan 7.
10
Comorbidities associated with mortality in 31,461 adults with COVID-19 in the United States: A federated electronic medical record analysis.美国 31461 例 COVID-19 成年人死亡相关合并症:一项联合电子病历分析。
PLoS Med. 2020 Sep 10;17(9):e1003321. doi: 10.1371/journal.pmed.1003321. eCollection 2020 Sep.

引用本文的文献

1
Risk factors for severe COVID-19 outcomes in the Asia-Pacific region: a literature review.亚太地区新冠重症结局的风险因素:文献综述
Front Public Health. 2025 Jun 9;13:1562179. doi: 10.3389/fpubh.2025.1562179. eCollection 2025.
2
Asthma and COPD as co-morbidities in patients hospitalised with Covid-19 disease: a global systematic review and meta-analysis.哮喘和 COPD 作为与 COVID-19 疾病住院患者共病的研究:全球系统回顾和荟萃分析。
BMC Pulm Med. 2023 Nov 22;23(1):462. doi: 10.1186/s12890-023-02761-5.
3
The Role of Diabetes and Hyperglycemia on COVID-19 Infection Course-A Narrative Review.

本文引用的文献

1
COVID-19 in unequally ageing European regions.欧洲老龄化程度不均地区的新冠疫情。
World Dev. 2020 Dec;136:105170. doi: 10.1016/j.worlddev.2020.105170. Epub 2020 Aug 28.
2
Comorbidity and its Impact on Patients with COVID-19.合并症及其对COVID-19患者的影响。
SN Compr Clin Med. 2020;2(8):1069-1076. doi: 10.1007/s42399-020-00363-4. Epub 2020 Jun 25.
3
Preexisting Comorbidities Predicting COVID-19 and Mortality in the UK Biobank Community Cohort.英国生物库社区队列中预测 COVID-19 和死亡率的预先存在的合并症。
糖尿病和高血糖对新型冠状病毒肺炎感染病程的影响——一篇叙述性综述
Front Clin Diabetes Healthc. 2022 Mar 10;3:812134. doi: 10.3389/fcdhc.2022.812134. eCollection 2022.
J Gerontol A Biol Sci Med Sci. 2020 Oct 15;75(11):2224-2230. doi: 10.1093/gerona/glaa183.
4
Effect of Underlying Comorbidities on the Infection and Severity of COVID-19 in Korea: a Nationwide Case-Control Study.韩国基础合并症对 COVID-19 感染和严重程度的影响:一项全国性病例对照研究。
J Korean Med Sci. 2020 Jun 29;35(25):e237. doi: 10.3346/jkms.2020.35.e237.
5
Patients with diabetes are at higher risk for severe illness from COVID-19.糖尿病患者感染 COVID-19 后出现重症的风险更高。
Diabetes Metab. 2020 Sep;46(4):335-337. doi: 10.1016/j.diabet.2020.05.001. Epub 2020 May 13.
6
Comorbid Chronic Diseases and Acute Organ Injuries Are Strongly Correlated with Disease Severity and Mortality among COVID-19 Patients: A Systemic Review and Meta-Analysis.合并慢性疾病和急性器官损伤与COVID-19患者的疾病严重程度和死亡率密切相关:一项系统评价和荟萃分析。
Research (Wash D C). 2020 Apr 19;2020:2402961. doi: 10.34133/2020/2402961. eCollection 2020.
7
Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes.COVID-19 合并 2 型糖尿病患者的血糖控制与结局的相关性。
Cell Metab. 2020 Jun 2;31(6):1068-1077.e3. doi: 10.1016/j.cmet.2020.04.021. Epub 2020 May 1.
8
Variation in COVID-19 Hospitalizations and Deaths Across New York City Boroughs.纽约市各行政区的 COVID-19 住院和死亡情况存在差异。
JAMA. 2020 Jun 2;323(21):2192-2195. doi: 10.1001/jama.2020.7197.
9
Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area.在纽约市地区,5700 名因 COVID-19 住院的患者的特征、合并症和结局。
JAMA. 2020 May 26;323(20):2052-2059. doi: 10.1001/jama.2020.6775.
10
Diabetes in COVID-19: Prevalence, pathophysiology, prognosis and practical considerations.2019冠状病毒病中的糖尿病:患病率、病理生理学、预后及实际考量
Diabetes Metab Syndr. 2020 Jul-Aug;14(4):303-310. doi: 10.1016/j.dsx.2020.04.004. Epub 2020 Apr 9.